Associated Papers
A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma.
Kang H et al.
The Journal of Clinical Investigation, 2025
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma.
Özoğul E et al.
Blood Cancer Journal, 2024
39313500 (PubMed )
Supplement: 41408_2024_1146_MOESM2_ESM.xlsx › S10
Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
Cao B et al.
Bmc Medical Genomics, 2024
38609996 (PubMed )
Supplement: 12920_2024_1866_MOESM1_ESM.pdf
BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL.
Xia M et al.
Cancer Discovery, 2022
BCL10 Mutants: Architects of Oncogenic Signaling Provide a Blueprint for Precision Medicine.
Phelan JD et al.
Cancer Discovery, 2022
Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms.
Lim MS et al.
American Journal of Clinical Pathology, 2019
Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas.
Jiang Y et al.
Genome Biology, 2014
25123191 (PubMed )
Supplement: 13059_2014_432_MOESM4_ESM.xlsx › Patient_2
Select a paper to view details